EVOLUTION DU PROCESSUS D'INNOVATION DANS LE ...

Delvaux

Sujets

• Économie
• Economy

Informations

• Publié par: paul.vallen
• Nombre de lectures: 21
• Langue: English

Extrait

EVOLUTION DU PROCESSUS D INNOVATION DANS LE SECTEUR ’ PHARMACEUTIQUE

Reinhard Angelmar Professeur de Marketing INSEAD, Fontainebleau

Les réseaux mondiaux d ’ innovation dans l ’ industrie pharmaceutique IFRI, 16 mars 2006

INNOVATION PROCESS: MAIN PHASES AND CONTRIBUTORS

POST- RE B S A E S A I R C CHR A E P S P E L A I R E C D H D P E R M V O E E D N L U T O C P T - C T L R I I NI A C L A S L APPROVAL M VE A I R S L K L U E A R T - N I C N E G

Public X Research

Small Biotech X Firms

Large Pharma X Firms

X

X

X

(X)

(X)

X

(X)

(X)

X

(X)

X

(X)

X

[e-mail]

U.S. BIOMEDICAL RESEARCH FUNDING

Source: Moses et al., JAMA, 2005

[e-mail]

R&D SPENDING BY SECTOR: EU TOP 500 COMPANIES, 2003

Sector FT classification

Sector R&D as a % of total

Sector R&D/Sales

[e-mail]

DECLINING R&D PRODUCTIVITY

rei

nhard.angelmar@i

nsead.edu

PHARMACEUTICAL FIRM SPENDING BY R&D PHASE

31.9% of R&D

Source: PhRMA, 2005

Phase I: Phase II: 6.8% 11.1%

Phase III: 23.3%

Approval: Phase IV: 12% 10.7%

[e-mail]

EVOLUTION OF PHARMA FIRM SPENDING BY R&D PHASE

1'100 1'000 900 800 700 600 500 400 300 200 100   -

Approval and regulatory Phase 4 Phase 1-3 Prehuman and preclinical

1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004

Source: Moses et al., JAMA, Sept. 21, 2005 (based on PhRMA)

[e-mail]

U.S. NME APPROVALS WITH PHASE IV COMMITMENTS

[e-mail]

•

•

HOW TO INCREASE R&D PRODUCTIVITY?

INCREASE OUTPUT – Increase number of projects entering development – Reduce attrition – Increase in-licensing and acquisitions (no impact on industry output)

REDUCE COSTS – Reduce attrition in Phases II & III – Increase speed – Reduce cost per patient

[e-mail]

Nr. OF ACTIVE DEVELOPMENT PROGRAMS

1800

1600

1400

1200

1000

800

600 400 200

0

Phase I Phase II Phase III

March 2001 March 2002 March 2003 March 2004 March 2005

Source: PARAXEL's Pharmaceutical R&D Statistical Sourcebook 2005/2006

[e-mail]

•

•

REDUCE ATTRITION

Early prediction of efficacy (proof-of-concept) and safety

Portfolio management – First-in-class; best-in-class; me-too; line extensions

– R&D / strategy-marketing alignment

[e-mail]